Endogenous peptide systems
The body produces hundreds of regulatory peptides: incretins from the gut, releasing hormones from the hypothalamus, natriuretic peptides from the heart, and many local mediators in tissue repair and immunity.
These systems are typically pulsatile and feedback-controlled. Introducing a long-acting external agonist changes the shape of that signal, not just its size — a distinction that often explains both efficacy and adverse effects.
Fig. 02 / Molecular pathwayReceptor downregulation and tolerance
Sustained receptor activation can reduce receptor density or responsiveness. This is one reason continuous stimulation is not automatically better than physiological pulses, and why trial designs test specific dosing schedules rather than 'more'.
Clearance and degradation
Peptidases in plasma and tissue, plus renal filtration, determine how long a peptide persists. Kidney and liver function therefore influence exposure, which is why clinical labelling for peptide medicines often includes organ-function considerations.
Fig. 03 / Evidence landscapeEditorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.